Research programme: Gram-positive infection therapeutics - ContraFect

Drug Profile

Research programme: Gram-positive infection therapeutics - ContraFect

Alternative Names: CF 302; CF 303; CF 304; CF 305; CF 306; CF-307; CF-308; CF-309; Gram-positive lysins - Contrafect

Latest Information Update: 24 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rockefeller University
  • Developer ContraFect
  • Class Enzymes; Recombinant proteins
  • Mechanism of Action Cell membrane inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Anthrax; Enterococcal infections; Pneumococcal infections; Streptococcal infections

Most Recent Events

  • 24 Nov 2016 Early research of CF 305 for Streptococcal agalactiae infections in USA (unspecified route) before November 2016 (Contrafect pipeline, November 2016)
  • 19 May 2014 Early research in Anthrax in USA (unspecified route)
  • 19 May 2014 Early research in Enterococcal infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top